The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer

PMID: 38018578
Journal: Immunity, inflammation and disease (volume: 11, issue: 11, Immun Inflamm Dis 2023 Nov;11(11):e1099)
Published: 2023-11-01

Authors:
Wang S, Zhang G, Cui Q, Yang Y, Wang D, Liu A, Xia Y, Li W, Liu Y, Yu J

ABSTRACT

The dendritic cell (DC)-T cell axis is a bridge that connects innate and adaptive immunities. The initial immune response against tumors is mainly induced by mature antigen-presenting DCs. Enhancing the crosstalk between DCs and T cells may be an effective approach to improve the immune response to non-small cell lung cancer (NSCLC). In this article, a review was made of the interaction between DCs and T cells in the treatment of NSCLC and how this interaction affects the treatment outcome.